Ranbaxy taking \'stringent steps\' to end US FDA ban

| Sep 21, 2013,

NEW DELHI: India\'s biggest drugmaker by sales, Ranbaxy Laboratories, has assured shareholders it is taking \"stringent steps\" to resolve a US ban on imports of medicines made at its newly renovated showcase plant.



The US Food and Drug Administration (FDA) banned imports last week from Ranbaxy\'s \"ultra modern\" Mohali plant, whose renovation was supposed to mark a turning point for the generics giant after years of run-ins with US regulators.



But now Mohali -- along with two other Ranbaxy plants placed under FDA bans earlier -- are unable to ship to the company\'s key US market due to for failing to meet \"good manufacturing practices\".


News From: http://www.7StarNews.com